Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients

  • Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease

     

  • Trial is designed and implemented quickly to address the need for science-based investigation following early preclinical and clinical evidence1,2,3 that hydroxychloroquine may help hospitalized patients with COVID-19 disease 
     
  • Company will also make its hydroxychloroquine intellectual property available to support broad access if …
/by

Novartis joins the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative

Novartis is teaming up with R&D leaders throughout the industry as part of the National Institutes of Health (NIH) and the Foundation for NIH (FNIH) Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) partnership initiative. Collaboration and open innovation are essential elements of the fight against this global pandemic. Novartis is committed to doing our part as an active contributor to the global effort underway to combat COVID-19.

About ACTIV

The National Institutes of Health and the Foundation for the NIH are bringing together more than a dozen …

/by

Novartis announces data in Neurology reinforcing the real-world and long-term effectiveness and safety of Aimovig® as a preventive treatment across the full spectrum of migraine

  • Real-world evidence supports benefits seen in Aimovig clinical trials
     
  • Open-label data highlight long-term efficacy and safety profile of Aimovig in episodic and chronic migraine
     
  • Post-hoc and real-world data show preventive treatment with Aimovig significantly reduces need for acute medications
     
  • These additional long-term data complement the position of Aimovig as the most prescribed anti-CGRP, with more than 350,000 patients prescribed worldwide since launch1 …
/by

Novartis ranks # 4 in PatientView’s 2019 corporate reputation survey of patient organizations

We are grateful to all patient organizations who have provided feedback on our work and take the opportunity to thank them for the hard work they are doing to support patients around the world, particularly in these challenging times of the COVID-19 crisis.

The Corporate Reputation of Pharma 2019 global report is based on the findings of a survey conducted by PatientView from November 2019 to February 2020.  

In this report Novartis ranked # 4 in overall reputation with patient organizations and # 2 in corporate brand awareness.

In our Commitment to Patients and …

/by

COVID-19: Answering your top questions

As a physician-scientist who has spent much of my career working on drug and vaccine development, including during the H1N1 pandemic, I’ve been getting many questions about my take on the COVID-19 response. I wanted to answer a few of the most common questions in case they’re on your mind as well.

How is the life sciences industry working together to combat COVID-19?

As I recently shared in an article on COVID-19, I believe we’re in the midst of by far the …

/by

Novartis completes safety review and initiates update to the Beovu® prescribing information worldwide

Basel, April 8, 2020 — Patient safety is at the heart of everything we do. Whenever adverse events are reported, we take them seriously and investigate them thoroughly.

As part of its safety surveillance program, Novartis has been actively evaluating post-marketing cases reported as severe vision loss, retinal artery occlusion and/or vasculitis with Beovu® (brolucizumab). We have been working closely with the reporting physicians and retina specialists to get their perspective and collect the relevant clinical and imaging data in a manner compliant with …

/by

World Chagas Disease Day 2020

Chagas disease is a major public health challenge. It affects approximately 6 million people1, mainly in Latin America. Less than 1% of affected individuals receive proper treatment2. 

For the first time, the global community is preparing to celebrate April, 14 as the first World Chagas Disease Day. One of the aims is to raise the visibility and public awareness of people with Chagas disease and the resources needed for the prevention, control or elimination of the disease3.

Chagas disease is one of four Novartis global health flagship programs …

/by

Novartis COVID-19 Response Fund provides support to healthcare workers and communities

Novartis is making rapid progress in distributing the allocated USD 20 million of the Novartis COVID-19 Response Fund, announced mid-March, to impacted countries around the world. The fund aims to support public health initiatives designed to help communities manage the challenges posed by the pandemic, such as programs to strengthen healthcare infrastructure, digital platforms for data collection or dissemination of important public health information, and community health programs. 

“We are managing this process with great efficiency and speed, aiming …

/by

Novartis announces first European donation of hydroxychloroquine to Switzerland

  • Novartis has committed to making a global donation of up to 130 million doses of the anti-malarial drug hydroxychloroquine to support efforts to fight the COVID-19 pandemic.
  • Sandoz, the generics and biosimilars division of Novartis, today begins delivering the first doses of hydroxychloroquine to the Swiss authorities, who are organizing its distribution to hospitals.
  • Switzerland becomes the first country in Europe, and the second globally after the USA, to receive a donation of this drug.

Rotkreuz, April 3, 2020 – Today, Novartis, …

/by

Novartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use program

  • New clinical trial to evaluate Jakavi® (ruxolitinib) in patients with COVID-19 associated cytokine storm
     
  • Cytokine storm is a type of severe immune overreaction that can result from coronavirus infection and may contribute to respiratory compromise in patients with COVID-191-3

  • Pre-clinical and preliminary clinical evidence suggests Jakavi, a well-established JAK inhibitor, could reduce the number of patients requiring intensive care and mechanical …
/by